image
Healthcare - Biotechnology - NASDAQ - US
$ 1.23
-6.11 %
$ 55.2 M
Market Cap
-0.75
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one HOWL stock under the worst case scenario is HIDDEN Compared to the current market price of 1.23 USD, Werewolf Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one HOWL stock under the base case scenario is HIDDEN Compared to the current market price of 1.23 USD, Werewolf Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 6, 2025.

The intrinsic value of one HOWL stock under the best case scenario is HIDDEN Compared to the current market price of 1.23 USD, Werewolf Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart HOWL

image
$2.0$2.0$1.8$1.8$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.615 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '25
FINANCIALS
1.88 M REVENUE
-90.55%
-73.6 M OPERATING INCOME
-81.70%
-70.5 M NET INCOME
-88.70%
-56.2 M OPERATING CASH FLOW
-72.29%
-254 K INVESTING CASH FLOW
66.97%
13.1 M FINANCING CASH FLOW
-77.61%
0 REVENUE
0.00%
0 OPERATING INCOME
100.00%
-18.1 M NET INCOME
11.33%
-18.9 M OPERATING CASH FLOW
-32.95%
0 INVESTING CASH FLOW
100.00%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Werewolf Therapeutics, Inc.
image
Current Assets 113 M
Cash & Short-Term Investments 111 M
Receivables 0
Other Current Assets 2.07 M
Non-Current Assets 13.9 M
Long-Term Investments 0
PP&E 12.3 M
Other Non-Current Assets 1.54 M
87.45 %9.71 %Total Assets$126.9m
Current Liabilities 15.2 M
Accounts Payable 3.04 M
Short-Term Debt 1.56 M
Other Current Liabilities 10.6 M
Non-Current Liabilities 38.4 M
Long-Term Debt 35.5 M
Other Non-Current Liabilities 2.83 M
5.67 %2.91 %19.78 %66.36 %5.28 %Total Liabilities$53.5m
EFFICIENCY
Earnings Waterfall Werewolf Therapeutics, Inc.
image
Revenue 1.88 M
Cost Of Revenue 0
Gross Profit 71 K
Operating Expenses 75.5 M
Operating Income -73.6 M
Other Expenses -3.08 M
Net Income -70.5 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)2m071k(75m)(74m)3m(71m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
3.77% GROSS MARGIN
3.77%
-3904.19% OPERATING MARGIN
-3904.19%
-3740.85% NET MARGIN
-3740.85%
-96.08% ROE
-96.08%
-55.55% ROA
-55.55%
-64.95% ROIC
-64.95%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Werewolf Therapeutics, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)202020202021202120222022202320232024202420252025
Net Income -70.5 M
Depreciation & Amortization 1.81 M
Capital Expenditures -254 K
Stock-Based Compensation 8.83 M
Change in Working Capital 2.53 M
Others -1.12 M
Free Cash Flow -56.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Werewolf Therapeutics, Inc.
image
HOWL has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Werewolf Therapeutics, Inc.
image
Sold
0-3 MONTHS
9.21 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
487 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Werewolf Therapeutics (HOWL) Upgraded to Buy: Here's What You Should Know Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. zacks.com - 2 weeks ago
Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference WATERTOWN, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer and Randi Isaacs, M.D., Chief Medical Officer, both of Werewolf Therapeutics, will participate in a fireside chat at 4:20 PM EDT on Thursday, June 5, 2025, at the Jefferies Global Healthcare Conference, taking place on June 3-5, 2025. globenewswire.com - 2 weeks ago
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 There are nearly 40,000 U.S. cases of cutaneous squamous cell carcinoma each year that advance to stages that are difficult to treat and life-threatening globenewswire.com - 3 weeks ago
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit WATERTOWN, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced Sameer Chopra, M.D., Ph.D., Vice President of Clinical Development, will speak during the Hanson Wade Cytokine-Based Drug Development Summit taking place May 15-16 in Boston, Massachusetts. globenewswire.com - 1 month ago
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update – WTX-124 Phase 1/1b clinical trial on track for data readouts and interactions with the FDA in the second half of the year – globenewswire.com - 1 month ago
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting - Data reveal WTX-921 is efficacious in a mouse colitis model, resulting in reduced tissue damage and inflammatory cytokine production - globenewswire.com - 1 month ago
Werewolf Therapeutics to Participate in Upcoming Investor Conferences WATERTOWN, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that management will participate in the following upcoming investor conferences in the month of May: globenewswire.com - 1 month ago
Earnings Preview: Werewolf Therapeutics, Inc. (HOWL) Q1 Earnings Expected to Decline Werewolf Therapeutics (HOWL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 1 month ago
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting. globenewswire.com - 1 month ago
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. globenewswire.com - 2 months ago
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update –  Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively – globenewswire.com - 3 months ago
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. globenewswire.com - 3 months ago
8. Profile Summary

Werewolf Therapeutics, Inc. HOWL

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 55.2 M
Dividend Yield 0.00%
Description Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Contact 1030 Massachusetts Avenue, Watertown, MA, 02138 https://werewolftx.com
IPO Date April 30, 2021
Employees 46
Officers Mr. Steven H. Bloom R.Ph. Chief Business Officer Dr. Chulani Karunatilake Ph.D. Chief Technology Officer Dr. Daniel J. Hicklin Ph.D. Founder, Chief Executive Officer, President, Secretary & Director Mr. Timothy W. Trost CPA Chief Financial Officer, Treasurer & Assistant Secretary Dr. Randi Isaacs M.D. Chief Medical Officer Dr. William Winston Ph.D. Senior Vice President of Research